Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine) + Hiberix (Haemophilus influenzae type b (Hib) vaccine)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Haemophilus Influenzae Type b (Hib) Infection
Conditions
Haemophilus Influenzae Type b (Hib) Infection
Trial Timeline
Sep 1, 2009 → Apr 1, 2010
NCT ID
NCT01025544About Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine) + Hiberix (Haemophilus influenzae type b (Hib) vaccine)
Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine) + Hiberix (Haemophilus influenzae type b (Hib) vaccine) is a phase 3 stage product being developed by Novartis for Haemophilus Influenzae Type b (Hib) Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01025544. Target conditions include Haemophilus Influenzae Type b (Hib) Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01025544 | Phase 3 | Completed |
Competing Products
10 competing products in Haemophilus Influenzae Type b (Hib) Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Comparator: Modified Process Vaccine + Comparator: COMVAX™ | Merck | Phase 3 | 77 |
| Vaxelis + PedvaxHIB | Merck | Approved | 85 |
| Haemophilus influenzae type b (Hib) vaccine | Novartis | Phase 3 | 77 |
| Haemophilus influenzae type b (Hib) vaccine | Novartis | Phase 3 | 77 |
| Haemophilus influenza type b conjugate vaccine | Novartis | Approved | 85 |
| Hib-CRM197 + Hib-TT | Novartis | Phase 3 | 77 |
| Haemophilus influenzae type b | Novartis | Phase 1 | 33 |
| Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib) + Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib) | Novartis | Phase 3 | 77 |
| Haemophilus influenzae type b vaccine + Commercial Haemophilus influenzae type b vaccine | Novartis | Phase 3 | 77 |
| DTaP-IPV/Hib | Sanofi | Pre-clinical | 22 |